Synapse - David Hyman

Results (354)

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

Meeting Abstract

Schram, A. M.; Drilon, A.; Macarulla Mercade, T.; O'Reilly, E. M.; Rodon, J. A.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C. H.; Lam, Y. C. J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase II study of olaparib in previously treated advanced solid tumours with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002

Meeting Abstract

Hyman, D.; Hendifar, A.; Cheol Chung, H.; Maio, M.; Leary, A.; Spanggaard, I.; Rhee, J.; Marton, M.; Chen, M.; Krishnan, S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)

Meeting Abstract

Drilon, A.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V.; Camidge, R. D.; Stopatschinskaja, S.; Cui, J. J.; Hyman, D. M.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results

Meeting Abstract

Borazanci, E.; Schram, A.; Brana, I.; Vieito Villar, M.; Garralda, E.; Spreafico, A.; Oliva, M.; Lakhani, N.; Wasserman, R.; Hoffman, K.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

A view on drug resistance in cancer

Review

Vasan, N.; Baselga, J.; Hyman, D. M.
Nature (2019)

Fulltext@MSK | Save

Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations

Meeting Abstract

Varghese, A. M.; Patel, J. A. A.; Janjigian, Y. Y.; Meng, F.; Selcuklu, S. D.; Zimel, C.; Hyman, D. M.; Iyer, G.; Houck-Loomis, B.; Abou-Alfa, G. K.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study

Meeting Abstract

Schram, A. M.; Benayed, R.; Somwar, R.; Rekhtman, N.; Arcila, M. E.; Ladanyi, M.; Hyman, D. M.; Drilon, A. E.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial

Meeting Abstract

Li, B. T.; Shen, R.; Offin, M.; Buonocore, D. J.; Myers, M. L.; Venkatesh, A.; Razavi, P.; Ginsberg, M. S.; Ulaner, G. A.; Solit, D. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect

Meeting Abstract

Hyman, D. M.; Zelnak, A. B.; Bauer, T. M.; Ulahannan, S. V.; Ford, J. M.; Cesari, R.; Hoyle, M.; Chappey, C.; Stewart, R.; Conte, U.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

FUZE clinical trial: A phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology

Meeting Abstract

Hyman, D. M.; Goyal, L.; Grivas, P.; Meric-Bernstam, F.; Tabernero, J.; Hu, Y.; Kirpicheva, Y.; Nicolas-Metral, V.; Pokorska-Bocci, A.; Vaslin, A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save